Kevin Feeley Sells 35,506 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 35,506 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $93.82, for a total transaction of $3,331,172.92. Following the transaction, the chief financial officer now owns 2,472 shares in the company, valued at approximately $231,923.04. The trade was a 93.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The shares were sold at an average price of $76.04, for a total value of $108,737.20.
• On Monday, December 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The stock was sold at an average price of $76.75, for a total value of $286,124.00.
• On Monday, December 9th, Kevin Feeley sold 1,137 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total transaction of $86,832.69.
• On Monday, December 2nd, Kevin Feeley sold 263 shares of GeneDx stock. The shares were sold at an average price of $78.39, for a total transaction of $20,616.57.
• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The stock was sold at an average price of $73.76, for a total transaction of $886,521.44.
• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The stock was sold at an average price of $66.60, for a total value of $18,248.40.

GeneDx Stock Performance

NASDAQ:WGS opened at $89.38 on Friday. The stock’s 50-day moving average is $78.01 and its 200-day moving average is $53.38. GeneDx Holdings Corp. has a 1-year low of $2.85 and a 1-year high of $98.87. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The stock has a market cap of $2.46 billion, a P/E ratio of -28.74 and a beta of 2.02.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.25. The business had revenue of $76.90 million for the quarter, compared to analysts’ expectations of $64.98 million. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The firm’s revenue for the quarter was up 44.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.82) EPS. Equities research analysts anticipate that GeneDx Holdings Corp. will post -0.24 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on WGS. Wells Fargo & Company boosted their price target on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 30th. TD Cowen increased their target price on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a report on Tuesday, January 7th. Craig Hallum raised their price target on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Finally, The Goldman Sachs Group upped their price objective on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, GeneDx currently has a consensus rating of “Moderate Buy” and an average target price of $70.67.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of WGS. Acadian Asset Management LLC bought a new position in GeneDx during the 2nd quarter valued at $34,000. CWM LLC purchased a new stake in shares of GeneDx in the third quarter valued at about $89,000. SG Americas Securities LLC bought a new position in shares of GeneDx during the third quarter valued at about $198,000. Point72 DIFC Ltd purchased a new position in GeneDx during the third quarter worth about $220,000. Finally, Palumbo Wealth Management LLC bought a new stake in GeneDx in the 3rd quarter worth about $287,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.